The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has been 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
L2 Bio, LLC Launches C-ROW Site Beta: A Breakthrough Research Project in Costa Rica Targeting Osteoarthritis
Innovative Participant-Funded Study Harnesses Enhanced Autologous Adipose-Derived Stem Cells to Combat Degenerative Joint Disease
ESCAZU, COSTA RICA, June 1,  2026 — L2 Bio, LLC has formally announced the launch of the C-ROW Site Beta (C-ROW), an innovative, participant-funded research project based in Costa Rica welcoming the safety and convenience of utilizing local participation of your USA or Canadian based doctor. The study centers on the use of enhanced autologous adipose-derived stem cells (ADSCs) to address the debilitating progression of osteoarthritis. [Read more…]
List of U.S. Cord Blood Banks – Public, Private, and Hybrid (2026)
A cord blood and tissue bank is a facility that collects, processes, and stores stem cells from a newborn’s umbilical cord blood and tissue for potential future use in medical treatments. These banks preserve the stem cells for therapies such as transplants for blood cancers or genetic disorders and may also store tissue for regenerative medicine applications​
This sortable list below includes all known Public, Private, and Hybrid Cord Blood Banks in the United States, including:
- Private cord blood banks store cord blood units for private use by individual families (for a fee)
- Public cord blood banks store cord blood donations for public use (free of cost)
- Hybrid cord blood banks offer both public and private cord blood banking services
Currently, Cord Blood Registry (CBR) is the largest U.S. cord blood bank with over one million cord blood and tissue units in storage. The next largest cord blood banks in the U.S. are Viacord and Cryo-Cell.
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Landmark data positions ERNA-101 as a potential game-changing immunotherapy and a major catalyst for future clinical and shareholder value
CAMBRIDGE, Mass., May 06, 2026 — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models. [Read more…]
FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media
-
Collaboration results in platform to help researchers overcome challenges in MSC research
-
NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences
SANTA ANA, Calif., USA and HUDDINGE, SWEDENÂ – FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences’Â PRIME-XV MSC Expansion XSFMÂ medium and NextCell’s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 337
- Next Page »